NCT00935532 - Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

427

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

September 30, 2010

Study Completion Date

July 31, 2011

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

exenatide once weekly

subcutaneous injection, 2.0mg, once a week;

DRUG

insulin glargine

subcutaneous injection, titrated to achieve fasting serum glucose target, once a day

Trial Locations (22)

Research Site, Aomori

Research Site, Chiba

Research Site, Ehime

Research Site, Fukuoka

Research Site, Gunma

Research Site, Hiroshima

Research Site, Hokkaido

Research Site, Hyōgo

Research Site, Ibaraki

Research Site, Kagawa

Research Site, Kanagawa

Research Site, Kumamoto

Research Site, Kyoto

Research Site, Nagano

Research Site, Nagasaki

Research Site, Nara

Research Site, Osaka

Research Site, Ōita

Research Site, Saitama

Research Site, Shizuoka

Research Site, Tokyo

Research Site, Toyama